Countries cannot publicly fund every possible medical treatment for every person without limits. They must decide which services to cover, for whom, under what clinical conditions, at what cost and with which health outcomes. The strongest systems make these choices through evidence-based, fair and transparent processes rather than leaving patients and doctors to discover unwritten restrictions at the hospital counter.
Imagine two treatments for the same illness. One is already widely used and affordable. The other is newly approved, costs far more, and provides a modest benefit for certain patients but not others. A regulator may allow the manufacturer to sell the new treatment. That does not automatically mean a national health insurer must pay for it.
This article explains how countries decide which treatments public healthcare covers. It focuses on the benefit-package and reimbursement decision—not on whether a person is eligible to enter the health system or how a small country purchases its stock of medicines.
Quick answer: decide what to fund, then make it accessible
A public payer or national health authority identifies important healthcare needs, reviews clinical evidence, considers the cost and expected benefits, consults relevant stakeholders, makes a lawful coverage decision and specifies how the funded treatment can be used.
The core chain is population health needs → candidate treatment → safety and efficacy evidence → comparative health benefit → cost and budget analysis → equity and ethical review → public reimbursement decision → provider funding and delivery → real patient outcomes → evidence-based reassessment.
A treatment can be licensed but unfunded; funded but restricted to particular patients; covered only after another treatment is tried; or covered through a temporary evidence-collection arrangement.
A sound explanation keeps these stages separate and records the decision date because both evidence and prices can change.
Three decisions people often confuse
Regulatory approval: Is a medicine, device or intervention legally authorised for the proposed use under the applicable product-safety and efficacy rules? The regulator addresses market authorisation, subject to the law.
Health technology assessment: What clinical, economic, social and ethical evidence supports using the intervention within a health system? Health technology assessment, or HTA, compares the technology with available alternatives and considers whether it brings sufficient value.
Public coverage or reimbursement: Has the responsible public payer decided to fund the treatment, for which people, in what setting, and under which conditions?
The World Health Organization’s description of health technology assessment explains how HTA informs adoption and reimbursement decisions. Regulatory approval ≠ public funding ≠ actual availability at a clinic.
Why even rich countries set limits
Health budgets compete with other healthcare needs: vaccination, primary care, maternity services, emergency treatment, specialist medicines, hospitals, mental health and long-term rehabilitation.
Every funded decision uses resources that could be spent elsewhere. If a government pays a high amount for one intervention, it may have less capacity to offer other treatments, reduce waiting times or build local care facilities.
WHO’s Principles of Health Benefit Packages notes that no country can provide every service to everyone. The task is to prioritise openly while moving toward universal health coverage.
The question therefore is not simply whether a treatment helps someone. It is who benefits, by how much, at what total cost, and what else the health system could do with the same resources.
What is a health benefit package?
A health benefit package describes services and goods that a public system has decided to fund, fully or partly, for a specified population.
It can include prevention, diagnosis, medicines, surgery, rehabilitation, palliative care and other healthcare interventions. Some countries publish a national list; others operate multiple coverage lists through insurance, hospitals or regional authorities.
The WHO’s benefit-design guidance emphasises that the package must explain not only what is included but the conditions of access and the extent of financial protection.
In practice, a label such as “covered” can still leave questions: Is a specialist referral required? Must previous treatments have failed? Is the medicine funded only at specified doses or for defined patients? Is a copayment due? Is the hospital authorised to provide the treatment?
A good system publishes these conditions in language patients and clinicians can use.
First measure whether the treatment works
Decision-makers review clinical trials, systematic reviews, real-world evidence where appropriate and relevant safety data. They ask what outcomes matter to patients: survival, symptoms, quality of life, hospitalisation, disability, adverse effects or the ability to return to everyday activities.
The correct comparison is usually a new treatment versus the best relevant available alternative, not versus no treatment in every case. Some trials show benefits for specific subgroups or have limited long-term follow-up.
Uncertainty matters. A new medicine may show promising short-term results but lack robust evidence about lasting benefit. Public payers should explain that uncertainty rather than presenting every newly licensed product as a proven major advance.
Different countries may reach different coverage decisions because their existing services, disease burdens, clinical evidence and negotiated prices are different.
What does cost-effectiveness mean?
Cost-effectiveness asks whether the additional health benefit is reasonable relative to the additional resources required compared with an alternative.
A treatment may be expensive but still offer good value if it produces substantial health gains or prevents future hospital treatment. A cheaper treatment may be poor value if it offers little improvement or causes serious harm.
Health economists may use measures such as quality-adjusted life years, disability-adjusted life years or other comparable outcomes, subject to the country’s methods.
The key is not that the cheapest medicine automatically wins. Cost-effectiveness compares both results and resource use. A country should explain the threshold, assumptions and uncertainty where it uses formal economic evaluation.
The WHO’s HTA and benefit-package resources describe how economic evidence supports transparent prioritisation and fairer health financing.
Cost-effectiveness is not the same as affordability this year
A treatment can appear cost-effective per patient but place a large burden on a national budget if very many people need it.
For example, a programme costing $2,000 per person and reaching 100 patients has an illustrative annual cost of $200,000. If 100,000 patients become eligible, that rises to $200 million. These are hypothetical calculations, not actual drug prices or reimbursement decisions.
The converse can also occur: a rare condition may affect very few people, so the total budget effect is relatively small even though the per-person price is high.
Public authorities therefore examine both value for money and budget impact. They may negotiate prices, phase access, establish clinical criteria or reassess funding as evidence improves.
Real example: NICE technology appraisals in England
England’s National Institute for Health and Care Excellence, NICE, evaluates many medicines and other treatments through its technology-appraisal process.
NICE explains that NHS funding is mandatory for treatments recommended by its technology appraisals within the terms of a recommendation. Where NICE recommends a treatment as an option, the NHS must normally ensure it is available within three months of publication, unless another timeframe is specified.
That does not mean every patient can demand every NICE-recommended product. The responsible clinician must determine that it is clinically appropriate, and any specified eligibility or treatment conditions apply.
This is a clear chain from assessment to payment obligation: review evidence → issue a defined recommendation → create a funding duty → make the appropriate treatment available → assess use against criteria.
Other NHS clinical guidelines may influence practice without having precisely the same mandatory funding status as a positive NICE technology appraisal. Different kinds of guidance must not be merged.
Real example: Australia’s Pharmaceutical Benefits Advisory Committee
Australia’s Pharmaceutical Benefits Advisory Committee (PBAC) reviews whether medicines should be recommended for listing on the national Pharmaceutical Benefits Scheme (PBS).
Its criteria include the medicine’s approved conditions of use, evidence of comparative safety and effectiveness, costs and wider health benefits such as quality of life. The PBAC can recommend restrictions, maximum quantities or repeats.
The process also distinguishes the committee’s recommendation from completion of the steps needed to place the treatment on the PBS schedule. A recommendation is not automatically the final subsidy listing.
This is an important public-administration difference from merely asking whether a medicine exists in Australia. A product can be authorised for sale yet await a favourable reimbursement recommendation or other steps before becoming subsidised for a particular indication.
A patient must check the current PBS listing, relevant restrictions and prescribing requirements.
Why two countries can fund the same drug differently
Imagine an identical medicine being assessed in two countries.
Country A already provides an effective low-cost alternative and negotiates a relatively high price for the new drug. Country B has fewer suitable alternatives, a different disease burden and negotiates a lower net price.
They might reach different reimbursement conclusions even if their doctors agree about the drug’s basic clinical effects.
Other differences can include local costs of hospital care, availability of trained staff, the number of eligible patients, national evaluation methods and equity priorities.
A responsible comparison does not assume that the country funding more products is automatically delivering better healthcare. It examines clinical outcomes, waiting times, total household cost and who is left without effective treatment.
Equity: when the economically efficient option is not the whole answer
Some interventions are expensive because the population benefiting is small, the treatment is complex or delivery requires specialist equipment far from urban centres.
A government must consider whether an apparently efficient average conceals unequal access for rural residents, disabled people, children or people with rare diseases.
WHO’s benefit-design guidance specifically explains that equity and financial protection may justify prioritising services for underserved communities rather than simply funding the lowest cost-per-patient opportunities.
This is a policy judgment with ethical and legal dimensions. It should be made through an explicit process instead of leaving individual clinics to ration invisibly or without explanation.
What happens when evidence is uncertain?
Coverage decisions do not always need to be a permanent yes or no.
Possible arrangements include funding only for defined patients, time-limited reviews, registries collecting outcomes, price agreements subject to legal constraints, or clinical trials and research programmes where appropriate.
A scheme must be careful about consent, data quality and realistic access. Patients should understand whether the medicine is part of routine funded care, a research study or a conditional arrangement.
When new evidence arrives—perhaps showing better survival, a previously unseen serious harm or a lower negotiated price—the authority may need to reconsider its decision.
A good coverage list has a procedure for revision, not just a date of publication.
Why defining the right patient group matters
A public payer might cover a medicine for severe disease after a first-line treatment has failed, but not for mild disease where cheaper effective options exist.
These conditions can be clinically reasonable when grounded in evidence, but they must be understandable and implemented consistently.
If a doctor prescribes outside the funded indication, the drug may still be legally available but not publicly reimbursed. The patient should not be misled into believing market authorisation and public subsidy are identical.
Patients need clarity on diagnosis, required evidence, authorised prescribers, reimbursement steps and the available routes for exceptional requests or review, subject to their country’s law.
Why a positive coverage decision can still fail
A treatment may be on a national list while local hospitals lack trained staff, operating theatre capacity, diagnostic tests or cold-chain storage.
The decision therefore needs an implementation plan: clinical training, procurement, sufficient budget, health information systems, distribution and patient communication.
This is particularly important for advanced medical technologies. A funded device may be useless without maintenance and qualified staff. A medicine may be approved and purchased but unavailable in remote clinics.
The companion article How Do Small Countries Buy Essential Medicines Reliably? addresses stock and supply once purchasing is authorised. This guide owns the prior question of which treatments public money should support.
How should decisions be published?
A reliable system should explain the responsible decision-maker, the medicine or service under review, the relevant patient group, key evidence, comparison treatment, costs and uncertainty, consultation opportunities and the final coverage status.
It should also show the effective date, any prescribing restrictions, the body responsible for funding, ways to correct a factual error and how reconsideration occurs when new evidence becomes available.
Public communication must distinguish not clinically recommended, not approved for sale, not yet publicly funded, funded only in specified circumstances, and available only through another programme.
These are not synonyms. Clear labels help patients avoid financial surprises and enable clinicians to follow valid rules.
Who pays when a treatment is excluded?
If public coverage does not include a treatment, households may seek private insurance, pay directly or pursue a lawful exceptional-funding or clinical-trial pathway.
A country must consider how these routes affect equity and financial protection. If only wealthy patients can access a potentially important treatment, the policy question remains even where the exclusion was reached through a legitimate process.
But the existence of hardship does not mean a treatment without adequate evidence should automatically be purchased by the state. Coverage institutions must balance individual needs with patient safety, public benefit and finite resources.
A fair process provides reasons and an appropriate route to appeal or request reconsideration under law, without promising that every appeal must succeed.
How to judge whether a national coverage system works
Use a scorecard that connects decision quality to patient outcomes:
- Clinical evidence: Were effectiveness, harms and alternatives properly assessed?
- Fairness: Was the decision transparent, consistent and open to relevant evidence?
- Affordability: What do patients and the public payer actually pay?
- Coverage: Which patients and indications qualify?
- Timeliness: How long does assessment and implementation take?
- Equity: Do rural, low-income and disabled patients face avoidable barriers?
- Implementation: Is the covered treatment actually available in an appropriate facility?
- Review: Are decisions updated when evidence or prices change?
Do not confuse a list of funded medicines with a measure of health outcomes. Patients must actually receive appropriate care.
Common misconceptions
“A regulator approved it, so the government must pay.” Market authorisation and public coverage are different decisions.
“The cheapest treatment always wins.” Assessment compares health outcomes, costs and wider policy priorities.
“One new treatment benefits every patient with that disease.” Clinical benefit and evidence may vary by subgroup.
“A positive recommendation guarantees immediate access everywhere.” Staff, funding, procurement and local delivery still matter.
“Every NHS guideline has the same funding rule.” Different guidance types have different legal and policy status.
“If Country A funds it and Country B does not, one must be irrational.” Evidence, alternatives, prices and resources can differ.
Frequently asked questions
What is a health benefit package?
It is a defined set of healthcare services or goods that a public system finances fully or partly for eligible people, under stated conditions.
Is cost-effectiveness the same as cost cutting?
No. It examines whether the additional resources produce worthwhile health benefits compared with relevant alternatives.
Can a publicly funded treatment have eligibility restrictions?
Yes. Funding may be limited to specified diagnoses, stages of disease, prescribers or previous treatment histories.
Does a new medicine become free when a regulator approves it?
No. Market approval and financial coverage are separate processes, and a funded service may still have lawful copayments.
Can a coverage decision change?
Yes. New evidence, changes in price, new treatments or policy review can alter decisions, subject to the relevant legal framework.
Country guides and internal links
For the national arrangements, see How the United Kingdom Works and How Australia Works.
The introductory guide How Do Countries Decide Which Public Services Residents Can Use? asks who qualifies for a public service. This article asks which treatments the public payer has agreed to fund.
The How Do Small Countries Buy Essential Medicines Reliably? guide focuses on ordering, shipping and stocking medicines rather than the reimbursement decision.
Return to How Countries Work | A–Z Guide to 195 Countries and Everyday Life.
Official sources and further reading
- WHO — Principles of Health Benefit Packages.
- WHO — Benefit design and health financing.
- WHO — Health technology assessment of medical devices, 2025.
- WHO — UHC Compendium.
- NICE — Technology appraisal guidance and NHS funding.
- Australia — Pharmaceutical Benefits Advisory Committee outcomes.
Evidence checked 21 October 2026. Medicine listings, NICE appraisals, funding timeframes and national benefit packages are updated over time. This explanation is not a personal treatment recommendation or a determination of coverage for a specific prescription.
Final takeaway
The public healthcare question is not only whether a treatment exists. It is whether the clinical evidence, expected benefit, cost, fairness and national funding rules justify providing it to an identifiable group of patients—and whether the health system can deliver it.
The whole system is evidence → priority → explicit coverage decision → finance and procurement → clinical eligibility → real treatment → measurable patient outcomes → review.